Teva on Thursday reported first quarter sales fell 19% versus the same period in 2018, as its top-seller Copaxone suffers from generic challenges and the company's own copycat business faces continued pricing pressure.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,